{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T08:41:09Z","timestamp":1792658469666,"version":"4.5.0"},"reference-count":88,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2013,1,1]],"date-time":"2013-01-01T00:00:00Z","timestamp":1356998400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2013,1]]},"DOI":"10.1007\/s40265-012-0005-z","type":"journal-article","created":{"date-parts":[[2013,1,10]],"date-time":"2013-01-10T16:55:19Z","timestamp":1357836919000},"page":"55-73","source":"Crossref","is-referenced-by-count":17,"title":["Ranolazine"],"prefix":"10.1007","volume":"73","author":[{"given":"Gillian M.","family":"Keating","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2013,1,11]]},"reference":[{"issue":"Suppl. 2","key":"5_CR1","first-page":"S2","volume":"19","author":"J Lopez-Sendon","year":"2012","unstructured":"Lopez-Sendon J, Purcell H, Camici P, et al. Chronic stable angina guidelines: is there an emerging international consensus? Br J Cardiol. 2012;19(Suppl. 2):S2\u201311.","journal-title":"Br J Cardiol."},{"issue":"15","key":"5_CR2","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1056\/NEJMoa070829","volume":"356","author":"WE Boden","year":"2007","unstructured":"Boden WE, O\u2019Rourke RA, Teo KK, et al. Optimal medical therapy with or without PCI for stable coronary disease. N Engl J Med. 2007;356(15):1503\u201316.","journal-title":"N Engl J Med."},{"issue":"8","key":"5_CR3","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1016\/j.jacc.2003.11.045","volume":"43","author":"BR Chaitman","year":"2004","unstructured":"Chaitman BR, Skettino SL, Parker JO, et al. Anti-ischemic effects and long-term survival during ranolazine monotherapy in patients with chronic severe angina. J Am Coll Cardiol. 2004;43(8):1375\u201382.","journal-title":"J Am Coll Cardiol."},{"key":"5_CR4","unstructured":"European Medicines Agency. Ranexa (ranolazine): EU summary of product characteristics. 2011. http:\/\/www.ema.europa.eu\/ema\/index.jsp?curl=pages\/medicines\/human\/medicines\/000805\/human_med_001009.jsp&mid=WC0b01ac058001d124 . Accessed 12 Sep 2012."},{"issue":"17","key":"5_CR5","doi-asserted-by":"crossref","first-page":"2483","DOI":"10.2165\/0003495-200868170-00006","volume":"68","author":"GM Keating","year":"2008","unstructured":"Keating GM. Ranolazine: a review of its use in chronic stable angina pectoris. Drugs. 2008;68(17):2483\u2013503.","journal-title":"Drugs."},{"issue":"5","key":"5_CR6","doi-asserted-by":"crossref","first-page":"469","DOI":"10.2165\/00003088-200645050-00003","volume":"45","author":"M Jerling","year":"2006","unstructured":"Jerling M. Clinical pharmacokinetics of ranolazine. Clin Pharmacokinet. 2006;45(5):469\u201391.","journal-title":"Clin Pharmacokinet."},{"issue":"4","key":"5_CR7","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1007\/s00392-007-0612-y","volume":"97","author":"G Hasenfuss","year":"2008","unstructured":"Hasenfuss G, Maier LS. Mechanism of action of the new anti-ischemia drug ranolazine. Clin Res Cardiol. 2008;97(4):222\u20136.","journal-title":"Clin Res Cardiol."},{"key":"5_CR8","doi-asserted-by":"crossref","unstructured":"Belardinelli L, Shryock JC, Fraser H. Inhibition of the late sodium current as a potential cardioprotective principle: effects of the late sodium current inhibitor ranolazine. Heart. 2006;92(Suppl. 4):iv6\u2013iv14.","DOI":"10.1136\/hrt.2005.078790"},{"issue":"4","key":"5_CR9","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1097\/FJC.0b013e3181a1b9e7","volume":"54","author":"LS Maier","year":"2009","unstructured":"Maier LS. A novel mechanism for the treatment of angina, arrhythmias, and diastolic dysfunction: inhibition of late INa using ranolazine. J Cardiovasc Pharmacol. 2009;54(4):279\u201386.","journal-title":"J Cardiovasc Pharmacol."},{"issue":"3","key":"5_CR10","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.pharmthera.2011.11.003","volume":"133","author":"S Sossalla","year":"2012","unstructured":"Sossalla S, Maier LS. Role of ranolazine in angina, heart failure, arrhythmias, and diabetes. Pharmacol Ther. 2012;133(3):311\u201323.","journal-title":"Pharmacol Ther."},{"issue":"8","key":"5_CR11","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1161\/01.CIR.0000139333.83620.5D","volume":"110","author":"C Antzelevitch","year":"2004","unstructured":"Antzelevitch C, Belardinelli L, Zygmunt AC, et al. Electrophysiological effects of ranolazine, a novel antianginal agent with antiarrhythmic properties. Circulation. 2004;110(8):904\u201310.","journal-title":"Circulation."},{"issue":"Suppl. 1","key":"5_CR12","doi-asserted-by":"crossref","first-page":"S169","DOI":"10.1111\/j.1540-8167.2006.00401.x","volume":"17","author":"AI Undrovinas","year":"2006","unstructured":"Undrovinas AI, Belardinelli L, Undrovinas NA, et al. Ranolazine improves abnormal repolarization and contraction in left ventricular myocytes of dogs with heart failure by inhibiting late sodium current. J Cardiovasc Electrophysiol. 2006;17(Suppl. 1):S169\u201377.","journal-title":"J Cardiovasc Electrophysiol."},{"issue":"2","key":"5_CR13","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1097\/00005344-200408000-00008","volume":"44","author":"Y Song","year":"2004","unstructured":"Song Y, Shryock JC, Wu L, et al. Antagonism by ranolazine of the pro-arrhythmic effects of increasing late INa in guinea pig ventricular myocytes. J Cardiovasc Pharmacol. 2004;44(2):192\u20139.","journal-title":"J Cardiovasc Pharmacol."},{"issue":"1","key":"5_CR14","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1124\/jpet.106.101832","volume":"318","author":"Y Song","year":"2006","unstructured":"Song Y, Shryock JC, Wagner S, et al. Blocking late sodium current reduces hydrogen peroxide-induced arrhythmogenic activity and contractile dysfunction. J Pharmacol Exp Ther. 2006;318(1):214\u201322.","journal-title":"J Pharmacol Exp Ther."},{"issue":"1","key":"5_CR15","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.yjmcc.2008.03.006","volume":"45","author":"S Sossalla","year":"2008","unstructured":"Sossalla S, Wagner S, Rasenack EC, et al. Ranolazine improves diastolic dysfunction in isolated myocardium from failing human hearts: role of late sodium current and intracellular ion accumulation. J Mol Cell Cardiol. 2008;45(1):32\u201343.","journal-title":"J Mol Cell Cardiol."},{"issue":"1","key":"5_CR16","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1038\/sj.bjp.0706709","volume":"148","author":"S Fredj","year":"2006","unstructured":"Fredj S, Sampson KJ, Liu H, et al. Molecular basis of ranolazine block of LQT-3 mutant sodium channels: evidence for site of action. Br J Pharmacol. 2006;148(1):16\u201324.","journal-title":"Br J Pharmacol."},{"issue":"5","key":"5_CR17","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1097\/FJC.0b013e318168e711","volume":"51","author":"XQ Zhang","year":"2008","unstructured":"Zhang XQ, Yamada S, Barry WH. Ranolazine inhibits an oxidative stress-induced increase in myocyte sodium and calcium loading during simulated-demand ischemia. J Cardiovasc Pharmacol. 2008;51(5):443\u20139.","journal-title":"J Cardiovasc Pharmacol."},{"issue":"6","key":"5_CR18","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1016\/j.yjmcc.2006.08.012","volume":"41","author":"H Fraser","year":"2006","unstructured":"Fraser H, Belardinelli L, Wang L, et al. Ranolazine decreases diastolic calcium accumulation caused by ATX-II or ischemia in rat hearts. J Mol Cell Cardiol. 2006;41(6):1031\u20138.","journal-title":"J Mol Cell Cardiol."},{"issue":"11","key":"5_CR19","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1016\/j.jcmg.2009.09.006","volume":"2","author":"R Venkataraman","year":"2009","unstructured":"Venkataraman R, Belardinelli L, Blackburn B, et al. A study of the effects of ranolazine using automated quantitative analysis of serial myocardial perfusion images. JACC Cardiovasc Imaging. 2009;2(11):1301\u20139.","journal-title":"JACC Cardiovasc Imaging."},{"issue":"3","key":"5_CR20","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1001\/jama.291.3.309","volume":"291","author":"BR Chaitman","year":"2004","unstructured":"Chaitman BR, Pepine CJ, Parker JO, et al. Effects of ranolazine with atenolol, amlodipine, or diltiazem on exercise tolerance and angina frequency in patients with severe chronic angina: a randomized controlled trial. JAMA. 2004;291(3):309\u201316.","journal-title":"JAMA."},{"issue":"6","key":"5_CR21","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1097\/FJC.0b013e31821458e8","volume":"57","author":"G Zhao","year":"2011","unstructured":"Zhao G, Walsh E, Shryock JC, et al. Antiadrenergic and hemodynamic effects of ranolazine in conscious dogs. J Cardiovasc Pharmacol. 2011;57(6):639\u201347.","journal-title":"J Cardiovasc Pharmacol."},{"issue":"12","key":"5_CR22","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1016\/j.jacc.2010.04.042","volume":"56","author":"PH Stone","year":"2010","unstructured":"Stone PH, Chaitman BR, Stocke K, et al. The anti-ischemic mechanism of action of ranolazine in stable ischemic heart disease. J Am Coll Cardiol. 2010;56(12):934\u201342.","journal-title":"J Am Coll Cardiol."},{"issue":"3","key":"5_CR23","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1016\/j.jacc.2006.05.044","volume":"48","author":"PH Stone","year":"2006","unstructured":"Stone PH, Gratsiansky NA, Blokhin A, et al. Antianginal efficacy of ranolazine when added to treatment with amlodipine: the ERICA (Efficacy of Ranolazine in Chronic Angina) trial. J Am Coll Cardiol. 2006;48(3):566\u201375.","journal-title":"J Am Coll Cardiol."},{"issue":"3","key":"5_CR24","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1007\/s12350-011-9364-1","volume":"18","author":"R Venkataraman","year":"2011","unstructured":"Venkataraman R, Aljaroudi W, Belardinelli L, et al. The effect of ranolazine on the vasodilator-induced myocardial perfusion abnormality. J Nucl Cardiol. 2011;18(3):456\u201362.","journal-title":"J Nucl Cardiol."},{"issue":"2","key":"5_CR25","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1124\/jpet.105.094862","volume":"316","author":"L Wu","year":"2006","unstructured":"Wu L, Shryock JC, Song Y, et al. An increase in late sodium current potentiates the proarrhythmic activities of low-risk QT-prolonging drugs in female rabbit hearts. J Pharmacol Exp Ther. 2006;316(2):718\u201326.","journal-title":"J Pharmacol Exp Ther."},{"issue":"2","key":"5_CR26","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1124\/jpet.104.066100","volume":"310","author":"L Wu","year":"2004","unstructured":"Wu L, Shryock JC, Song Y, et al. Antiarrhythmic effects of ranolazine in a guinea pig in vitro model of long-QT syndrome. J Pharmacol Exp Ther. 2004;310(2):599\u2013605.","journal-title":"J Pharmacol Exp Ther."},{"issue":"3","key":"5_CR27","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1124\/jpet.108.137729","volume":"325","author":"W-Q Wang","year":"2008","unstructured":"Wang W-Q, Robertson C, Dhalla AK, et al. Antitorsadogenic effects of (\u00b1)-N-(2,6-dimethyl-phenyl)-(4[2-hydroxy-3-(2-methoxyphenoxy)propyl]-1-piperazine (ranolazine) in anesthetized rabbits. J Pharmacol Exp Ther. 2008;325(3):875\u201381.","journal-title":"J Pharmacol Exp Ther."},{"issue":"8","key":"5_CR28","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1038\/sj.bjp.0705879","volume":"142","author":"G Schram","year":"2004","unstructured":"Schram G, Zhang L, Derakhchan K, et al. Ranolazine: ion-channel-blocking actions and in vivo electrophysiological effects. Br J Pharmacol. 2004;142(8):1300\u20138.","journal-title":"Br J Pharmacol."},{"issue":"2","key":"5_CR29","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1177\/107424849600100208","volume":"1","author":"MR Gralinski","year":"1996","unstructured":"Gralinski MR, Chi L, Park JL, et al. Protective effects of ranolazine on ventricular fibrillation induced by activation of the ATP-dependent potassium channel in the rabbit heart. J Cardiovasc Pharmacol Ther. 1996;1(2):141\u20138.","journal-title":"J Cardiovasc Pharmacol Ther."},{"issue":"4","key":"5_CR30","doi-asserted-by":"crossref","first-page":"e36","DOI":"10.1111\/j.1755-5922.2010.00203.x","volume":"29","author":"RA Kloner","year":"2011","unstructured":"Kloner RA, Dow JS, Bhandari A. The antianginal agent ranolazine is a potent antiarrhythmic agent that reduces ventricular arrhythmias: through a mechanism favoring inhibition of late sodium channel. Cardiovasc Ther. 2011;29(4):e36\u201341.","journal-title":"Cardiovasc Ther."},{"issue":"7","key":"5_CR31","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1016\/j.hrthm.2008.03.018","volume":"5","author":"S Sicouri","year":"2008","unstructured":"Sicouri S, Glass A, Belardinelli L, et al. Antiarrhythmic effects of ranolazine in canine pulmonary vein sleeve preparations. Heart Rhythm. 2008;5(7):1019\u201326.","journal-title":"Heart Rhythm."},{"issue":"5","key":"5_CR32","doi-asserted-by":"crossref","first-page":"H1923","DOI":"10.1152\/ajpheart.00173.2009","volume":"297","author":"AK Dhalla","year":"2009","unstructured":"Dhalla AK, Wang W-Q, Dow J, et al. Ranolazine, an antianginal agent, markedly reduces ventricular arrhythmias induced by ischemia and ischemia-reperfusion. Am J Physiol Heart Circ Physiol. 2009;297(5):H1923\u20139.","journal-title":"Am J Physiol Heart Circ Physiol."},{"issue":"10","key":"5_CR33","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1111\/j.1540-8167.2008.01204.x","volume":"19","author":"K Kumar","year":"2008","unstructured":"Kumar K, Nearing BD, Bartoli CR, et al. Effect of ranolazine on ventricular vulnerability and defibrillation threshold in the intact porcine heart. J Cardiovasc Electrophysiol. 2008;19(10):1073\u20139.","journal-title":"J Cardiovasc Electrophysiol."},{"issue":"3","key":"5_CR34","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1016\/j.jacc.2010.07.045","volume":"57","author":"N Morita","year":"2011","unstructured":"Morita N, Lee JH, Xie Y, et al. Suppression of re-entrant and multifocal ventricular fibrillation by the late sodium current blocker ranolazine. J Am Coll Cardiol. 2011;57(3):366\u201375.","journal-title":"J Am Coll Cardiol."},{"issue":"1","key":"5_CR35","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1254\/jjp.77.31","volume":"77","author":"H Matsumura","year":"1998","unstructured":"Matsumura H, Hara A, Hashizume H, et al. Protective effects of ranolazine, a novel anti-ischemic drug, on the hydrogen peroxide-induced derangements in isolated, perfused rat heart: comparison with dichloroacetate. Jpn J Pharmacol. 1998;77(1):31\u20139.","journal-title":"Jpn J Pharmacol."},{"issue":"Suppl. 1","key":"5_CR36","doi-asserted-by":"crossref","first-page":"S16","DOI":"10.1161\/CIRCULATIONAHA.108.844167","volume":"120","author":"H Hwang","year":"2009","unstructured":"Hwang H, Arcidi JM Jr, Hale SL, et al. Ranolazine as a cardioplegia additive improves recovery of diastolic function in isolated rat hearts. Circulation. 2009;120(Suppl. 1):S16\u201321.","journal-title":"Circulation."},{"issue":"2","key":"5_CR37","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1177\/1074248409333491","volume":"14","author":"H Hwang","year":"2009","unstructured":"Hwang H, Arcidi JM Jr, Hale SL, et al. Ranolazine as an adjunct to cardioplegia: a potential new therapeutic application. J Cardiovasc Pharmacol Ther. 2009;14(2):125\u201333.","journal-title":"J Cardiovasc Pharmacol Ther."},{"issue":"5","key":"5_CR38","doi-asserted-by":"crossref","first-page":"H2149","DOI":"10.1152\/ajpheart.00728.2008","volume":"295","author":"S Rastogi","year":"2008","unstructured":"Rastogi S, Sharov VG, Mishra S, et al. Ranolazine combined with enalapril or metoprolol prevents progressive LV dysfunction and remodeling in dogs with moderate heart failure. Am J Physiol Heart Circ Physiol. 2008;295(5):H2149\u201355.","journal-title":"Am J Physiol Heart Circ Physiol."},{"issue":"8","key":"5_CR39","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1093\/cvr\/28.8.1231","volume":"28","author":"MR Gralinski","year":"1994","unstructured":"Gralinski MR, Black SC, Kilgore KS, et al. Cardioprotective effects of ranolazine (RS-43285) in the isolated perfused rabbit heart. Cardiovasc Res. 1994;28(8):1231\u20137.","journal-title":"Cardiovasc Res."},{"issue":"6","key":"5_CR40","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1054\/jcaf.2002.129232","volume":"8","author":"HN Sabbah","year":"2002","unstructured":"Sabbah HN, Chandler MP, Mishima T, et al. Ranolazine, a partial fatty acid oxidation (pFOX) inhibitor, improves left ventricular function in dogs with chronic heart failure. J Card Fail. 2002;8(6):416\u201322.","journal-title":"J Card Fail."},{"issue":"4","key":"5_CR41","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1161\/01.RES.0000031151.21145.59","volume":"91","author":"MP Chandler","year":"2002","unstructured":"Chandler MP, Stanley WC, Morita H, et al. Short-term treatment with ranolazine improves mechanical efficiency in dogs with chronic heart failure. Circ Res. 2002;91(4):278\u201380.","journal-title":"Circ Res."},{"issue":"5","key":"5_CR42","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1007\/BF00877121","volume":"8","author":"W Hayashida","year":"1994","unstructured":"Hayashida W, van Eyll C, Rousseau MF, et al. Effects of ranolazine on left ventricular regional diastolic function in patients with ischemic heart disease. Cardiovasc Drugs Ther. 1994;8(5):741\u20137.","journal-title":"Cardiovasc Drugs Ther."},{"issue":"12","key":"5_CR43","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1111\/j.1540-8167.2008.01246.x","volume":"19","author":"AJ Moss","year":"2008","unstructured":"Moss AJ, Zareba W, Schwarz KQ, et al. Ranolazine shortens repolarization in patients with sustained inward sodium current due to type-3 long-QT syndrome. J Cardiovasc Electrophysiol. 2008;19(12):1289\u201393.","journal-title":"J Cardiovasc Electrophysiol."},{"key":"5_CR44","unstructured":"Maier L, Wachter R, Edelmann F, et al. Ranolazine for the treatment of diastolic heart failure in patients with preserved ejection fraction: results from the RALI-DHF study (abstract no. 921-8). 61st Annual Scientific Sessions of the American College of Cardiology, Chicago 24\u201327 Mar 2012."},{"issue":"7","key":"5_CR45","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1002\/clc.20897","volume":"34","author":"C Jacobshagen","year":"2011","unstructured":"Jacobshagen C, Belardinelli L, Hasenfuss G, et al. Ranolazine for the treatment of heart failure with preserved ejection fraction: background, aims, and design of the RALI-DHF study. Clin Cardiol. 2011;34(7):426\u201332.","journal-title":"Clin Cardiol."},{"issue":"2","key":"5_CR46","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1177\/1074248410382105","volume":"16","author":"VM Figueredo","year":"2011","unstructured":"Figueredo VM, Pressman GS, Romero-Corral A, et al. Improvement in left ventricular systolic and diastolic performance during ranolazine treatment in patients with stable angina. J Cardiovasc Pharmacol Ther. 2011;16(2):168\u201372.","journal-title":"J Cardiovasc Pharmacol Ther"},{"issue":"10","key":"5_CR47","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1016\/j.amjcard.2012.06.055","volume":"110","author":"R Venkataraman","year":"2012","unstructured":"Venkataraman R, Chen J, Garcia EV, et al. Effect of ranolazine on left ventricular dyssynchrony in patients with coronary artery disease. Am J Cardiol. 2012;110(10):1440\u20135.","journal-title":"Am J Cardiol."},{"issue":"1","key":"5_CR48","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1093\/eurheartj\/ehi495","volume":"27","author":"AD Timmis","year":"2006","unstructured":"Timmis AD, Chaitman BR, Crager M. Effects of ranolazine on exercise tolerance and HbA1c in patients with chronic angina and diabetes. Eur Heart J. 2006;27(1):42\u20138.","journal-title":"Eur Heart J."},{"issue":"15","key":"5_CR49","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.1161\/CIRCULATIONAHA.107.763912","volume":"119","author":"DA Morrow","year":"2009","unstructured":"Morrow DA, Scirica BM, Chaitman BR, et al. Evaluation of the glycometabolic effects of ranolazine in patients with and without diabetes mellitus in the MERLIN-TIMI 36 randomized controlled trial. Circulation. 2009;119(15):2032\u20139.","journal-title":"Circulation."},{"issue":"6","key":"5_CR50","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.2337\/dc09-2334","volume":"33","author":"JW Chisholm","year":"2010","unstructured":"Chisholm JW, Goldfine AB, Dhalla AK, et al. Effect of ranolazine on A1C and glucose levels in hyperglycemic patients with non-ST elevation acute coronary syndrome. Diabetes Care. 2010;33(6):1163\u20138.","journal-title":"Diabetes Care."},{"issue":"1","key":"5_CR51","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1124\/jpet.110.176396","volume":"337","author":"Y Ning","year":"2011","unstructured":"Ning Y, Zhen W, Fu Z, et al. Ranolazine increases \u03b2-cell survival and improves glucose homeostasis in low-dose streptozotocin-induced diabetes in mice. J Pharmacol Exp Ther. 2011;337(1):50\u20138.","journal-title":"J Pharmacol Exp Ther."},{"issue":"5","key":"5_CR52","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1097\/MCA.0b013e32832a198b","volume":"20","author":"SH Deshmukh","year":"2009","unstructured":"Deshmukh SH, Patel SR, Pinassi E, et al. Ranolazine improves endothelial function in patients with stable coronary artery disease. Coron Artery Dis. 2009;20(5):343\u20137.","journal-title":"Coron Artery Dis."},{"issue":"14","key":"5_CR53","doi-asserted-by":"crossref","first-page":"1418","DOI":"10.1002\/rcm.1290091419","volume":"9","author":"AD Penman","year":"1995","unstructured":"Penman AD, Eadie J, Herron WJ, et al. The characterization of the metabolites of ranolazine in man by liquid chromatography mass spectrometry. Rapid Commun Mass Spectrom. 1995;9(14):1418\u201330.","journal-title":"Rapid Commun Mass Spectrom"},{"issue":"3","key":"5_CR54","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/j.clpt.2005.05.004","volume":"78","author":"M Jerling","year":"2005","unstructured":"Jerling M, Abdallah H. Effect of renal impairment on multiple-dose pharmacokinetics of extended-release ranolazine. Clin Pharmacol Ther. 2005;78(3):288\u201397.","journal-title":"Clin Pharmacol Ther."},{"issue":"7","key":"5_CR55","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1177\/0091270005276739","volume":"45","author":"H Abdallah","year":"2005","unstructured":"Abdallah H, Jerling M. Effect of hepatic impairment on the multiple-dose pharmacokinetics of ranolazine sustained-release tablets. J Clin Pharmacol. 2005;45(7):802\u20139.","journal-title":"J Clin Pharmacol."},{"issue":"4","key":"5_CR56","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1177\/0091270004273992","volume":"45","author":"M Jerling","year":"2005","unstructured":"Jerling M, Huan B-L, Leung K, et al. Studies to investigate the pharmacokinetic interactions between ranolazine and ketoconazole, diltiazem, or simvastatin during combined administration in healthy subjects. J Clin Pharmacol. 2005;45(4):422\u201333.","journal-title":"J Clin Pharmacol."},{"issue":"9","key":"5_CR57","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1177\/0091270009337512","volume":"49","author":"X Wang","year":"2009","unstructured":"Wang X, Bingham J, DeVault A, et al. Pharmacokinetic interaction between ranolazine and the CYP2D6 substrate metoprolol in healthy volunteers (abstract no. 72). J Clin Pharmacol. 2009;49(9):1107.","journal-title":"J Clin Pharmacol."},{"issue":"16","key":"5_CR58","doi-asserted-by":"crossref","first-page":"1775","DOI":"10.1001\/jama.297.16.1775","volume":"297","author":"DA Morrow","year":"2007","unstructured":"Morrow DA, Scirica BM, Karwatowska-Prokopczuk E, et al. Effects of ranolazine on recurrent cardiovascular events in patients with non-ST-elevation acute coronary syndromes: the MERLIN-TIMI 36 randomized trial. JAMA. 2007;297(16):1775\u201383.","journal-title":"JAMA."},{"issue":"14","key":"5_CR59","doi-asserted-by":"crossref","first-page":"E1050","DOI":"10.1016\/S0735-1097(11)61050-4","volume":"57","author":"NM Bennett","year":"2011","unstructured":"Bennett NM, Arndt TL, Iyer V, et al. Ranolazine refractory angina registry trial: 1-year results (abstract no. 1074\u2013362). J Am Coll Cardiol. 2011;57(14):E1050.","journal-title":"J Am Coll Cardiol."},{"issue":"5","key":"5_CR60","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1177\/2047487312450133","volume":"19","author":"J L\u00f3pez-Send\u00f3n","year":"2012","unstructured":"L\u00f3pez-Send\u00f3n J, Lee S, Cheng ML, et al. Effects of ranolazine on exercise tolerance and angina frequency in patients with severe chronic angina receiving maximally-tolerated background therapy: analysis from the Combination Assessment of Ranolazine In Stable Angina (CARISA) randomized trial. Eur J Prev Cardiol. 2012;19(5):952\u20139.","journal-title":"Eur J Prev Cardiol."},{"key":"5_CR61","unstructured":"White HD, Skettino S, Chaitman BR, et al. Anti-anginal efficacy of ranolazine addition to beta blocker or calcium antagonist therapy in patients with a history of heart failure (abstract no. 1746). Circulation. 2002;106 (19 Suppl. 2):349\u201350."},{"issue":"1","key":"5_CR62","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.amjcard.2006.07.052","volume":"99","author":"NK Wenger","year":"2007","unstructured":"Wenger NK, Chaitman B, Vetrovec GW. Gender comparison of efficacy and safety of ranolazine for chronic angina pectoris in four randomized clinical trials. Am J Cardiol. 2007;99(1):11\u20138.","journal-title":"Am J Cardiol."},{"issue":"4","key":"5_CR63","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1111\/j.1076-7460.2007.07119.x","volume":"16","author":"MW Rich","year":"2007","unstructured":"Rich MW, Crager M, McKay CR. Safety and efficacy of extended-release ranolazine in patients aged 70\u00a0years or older with chronic stable angina pectoris. Am J Geriatr Cardiol. 2007;16(4):216\u201321.","journal-title":"Am J Geriatr Cardiol."},{"issue":"2","key":"5_CR64","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1161\/CIRCOUTCOMES.108.798009","volume":"1","author":"SV Arnold","year":"2008","unstructured":"Arnold SV, Morrow DA, Wang K, et al. Effects of ranolazine on disease-specific health status and quality of life among patients with acute coronary syndromes: results from the MERLIN-TIMI 36 randomized trial. Circ Cardiovasc Qual Outcomes. 2008;1(2):107\u201315.","journal-title":"Circ Cardiovasc Qual Outcomes."},{"issue":"17","key":"5_CR65","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.1016\/j.jacc.2009.01.037","volume":"53","author":"SR Wilson","year":"2009","unstructured":"Wilson SR, Scirica BM, Braunwald E, et al. Efficacy of ranolazine in patients with chronic angina: observations from the randomized, double-blind, placebo-controlled MERLIN-TIMI (Metabolic Efficiency With Ranolazine for Less Ischemia in Non-ST-Segment Elevation Acute Coronary Syndromes) 36 Trial. J Am Coll Cardiol. 2009;53(17):1510\u20136.","journal-title":"J Am Coll Cardiol."},{"issue":"16","key":"5_CR66","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1161\/CIRCULATIONAHA.109.897231","volume":"121","author":"JL Mega","year":"2010","unstructured":"Mega JL, Hochman JS, Scirica BM, et al. Clinical features and outcomes of women with unstable ischemic heart disease: observations from metabolic efficiency with ranolazine for less ischemia in non-ST-elevation acute coronary syndromes-thrombolysis in myocardial infarction 36 (MERLIN-TIMI 36). Circulation. 2010;121(16):1809\u201317.","journal-title":"Circulation."},{"issue":"12","key":"5_CR67","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1016\/j.jacc.2009.09.068","volume":"55","author":"DA Morrow","year":"2010","unstructured":"Morrow DA, Scirica BM, Sabatine MS, et al. B-type natriuretic peptide and the effect of ranolazine in patients with non-ST-segment elevation acute coronary syndromes: observations from the MERLIN-TIMI 36 (Metabolic Efficiency With Ranolazine for Less Ischemia in Non-ST Elevation Acute Coronary-Thrombolysis In Myocardial Infarction 36) trial. J Am Coll Cardiol. 2010;55(12):1189\u201396.","journal-title":"J Am Coll Cardiol."},{"issue":"16","key":"5_CR68","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1016\/j.jacc.2008.12.053","volume":"53","author":"BM Scirica","year":"2009","unstructured":"Scirica BM, Morrow DA, Budaj A, et al. Ischemia detected on continuous electrocardiography after acute coronary syndrome: observations from the MERLIN-TIMI 36 (Metabolic Efficiency With Ranolazine for Less Ischemia in Non-ST-Elevation Acute Coronary Syndrome-Thrombolysis In Myocardial Infarction 36) trial. J Am Coll Cardiol. 2009;53(16):1411\u201321.","journal-title":"J Am Coll Cardiol."},{"issue":"10","key":"5_CR69","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1016\/j.jacc.2006.10.067","volume":"49","author":"MJ Koren","year":"2007","unstructured":"Koren MJ, Crager MR, Sweeney M. Long-term safety of a novel antianginal agent in patients with severe chronic stable angina: the Ranolazine Open Label Experience (ROLE). J Am Coll Cardiol. 2007;49(10):1027\u201334.","journal-title":"J Am Coll Cardiol."},{"issue":"15","key":"5_CR70","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1161\/CIRCULATIONAHA.107.724880","volume":"116","author":"BM Scirica","year":"2007","unstructured":"Scirica BM, Morrow DA, Hod H, et al. Effect of ranolazine, an antianginal agent with novel electrophysiological properties, on the incidence of arrhythmias in patients with non-ST-segment-elevation acute coronary syndrome: results from the metabolic efficiency with ranolazine for less ischemia in non-ST-elevation acute coronary syndrome-thrombolysis in myocardial infarction 36 (MERLIN-TIMI 36) randomized controlled trial. Circulation. 2007;116(15):1647\u201352.","journal-title":"Circulation."},{"issue":"5","key":"5_CR71","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1161\/CIRCULATIONAHA.110.937136","volume":"122","author":"BM Scirica","year":"2010","unstructured":"Scirica BM, Braunwald E, Belardinelli L, et al. Relationship between nonsustained ventricular tachycardia after non-ST-elevation acute coronary syndrome and sudden cardiac death: observations from the metabolic efficiency with ranolazine for less ischemia in non-ST-elevation acute coronary syndrome-thrombolysis in myocardial infarction 36 (MERLIN-TIMI 36) randomized controlled trial. Circulation. 2010;122(5):455\u201362.","journal-title":"Circulation."},{"key":"5_CR72","unstructured":"Scirica BM, Belardinelli L, Chaitman BR, et al. Effect of ranolazine on atrial fibrillation among patients with non-ST elevation acute coronary syndromes (NSTEACS): observations from the MERLIN-TIMI 36 trial (abstract no. 13798). Circulation. 2011;124(21 suppl 1)"},{"issue":"12","key":"5_CR73","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1016\/j.jacc.2010.07.010","volume":"56","author":"WE Boden","year":"2010","unstructured":"Boden WE. Ranolazine and its anti-ischemic effects: revisiting an old mechanistic paradigm anew? J Am Coll Cardiol. 2010;56(12):943\u20135.","journal-title":"J Am Coll Cardiol."},{"key":"5_CR74","unstructured":"National Institute for Health and Clinical Excellence. Management of stable angina. 2011. http:\/\/www.nice.org.uk\/nicemedia\/live\/13549\/55660\/55660.pdf . Accessed 27 Sep 2012."},{"issue":"8","key":"5_CR75","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/j.amjmed.2011.02.036","volume":"124","author":"PC Deedwania","year":"2011","unstructured":"Deedwania PC, Carbajal EV. Medical therapy versus myocardial revascularization in chronic coronary syndrome and stable angina. Am J Med. 2011;124(8):681\u20138.","journal-title":"Am J Med."},{"issue":"4","key":"5_CR76","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1007\/s12325-010-0018-5","volume":"27","author":"S Aslam","year":"2010","unstructured":"Aslam S, Gray D. Ranolazine (Ranexa\u00ae) in the treatment of chronic stable angina. Adv Ther. 2010;27(4):193\u2013201.","journal-title":"Adv Ther."},{"key":"5_CR77","first-page":"535","volume":"7","author":"AA Truffa","year":"2011","unstructured":"Truffa AA, Newby LK, Melloni C. Extended-release ranolazine: critical evaluation of its use in stable angina. Vasc Health Risk Manag. 2011;7:535\u20139.","journal-title":"Vasc Health Risk Manag."},{"key":"5_CR78","doi-asserted-by":"crossref","unstructured":"Zuchi C, Tritto I, Ambrosio G. Angina pectoris in women: focus on microvascular disease. Epub Int J Cardiol; 2012","DOI":"10.1016\/j.ijcard.2012.07.001"},{"issue":"5","key":"5_CR79","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1016\/j.jcmg.2011.03.007","volume":"4","author":"PK Mehta","year":"2011","unstructured":"Mehta PK, Goykhman P, Thomson LEJ, et al. Ranolazine improves angina in women with evidence of myocardial ischemia but no obstructive coronary artery disease. JACC Cardiovasc Imaging. 2011;4(5):514\u201322.","journal-title":"JACC Cardiovasc Imaging."},{"key":"5_CR80","unstructured":"Belsey J, Vardas P, Camm J. Relative efficacy of antianginal drugs used in an add-on role in patients with stable angina: systematic review and meta-analysis (abstract no. 15298). Circulation. 2012;126(21 Suppl.)."},{"key":"5_CR81","unstructured":"European Medicines Agency. Corlentor (ivabradine): EU summary of product characteristics. 2012. http:\/\/www.emea.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/000598\/WC500035341.pdf . Accessed 19 Nov 2012."},{"issue":"3","key":"5_CR82","doi-asserted-by":"crossref","first-page":"136","DOI":"10.3909\/ricm0572","volume":"12","author":"E Cingolani","year":"2011","unstructured":"Cingolani E, Lepor NE, Singh BN. The electrophysiological properties of ranolazine: a metabolic anti-ischemic drug or an energy-efficient antiarrhythmic agent? Rev Cardiovasc Med. 2011;12(3):136\u201342.","journal-title":"Rev Cardiovasc Med"},{"issue":"1","key":"5_CR83","first-page":"705","volume":"2","author":"DK Murdock","year":"2010","unstructured":"Murdock DK, Reiffel JA, Kaliebe J, et al. The conversion of paroxysmal or initial onset atrial fibrillation with oral ranolazine: implications for a new \u2018pill-in-pocket\u2019 approach in structural heart disease. J Atr Fibrillation. 2010;2(1):705\u201310.","journal-title":"J Atr Fibrillation."},{"issue":"3","key":"5_CR84","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1111\/j.1540-8159.2011.03298.x","volume":"35","author":"DK Murdock","year":"2012","unstructured":"Murdock DK, Kaliebe J, Larrain G. The use of ranolazine to facilitate electrical cardioversion in cardioversion-resistant patients: a case series. Pacing Clin Electrophysiol. 2012;35(3):302\u20137.","journal-title":"Pacing Clin Electrophysiol."},{"issue":"5","key":"5_CR85","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1016\/j.amjcard.2012.04.044","volume":"110","author":"N Fragakis","year":"2012","unstructured":"Fragakis N, Koskinas KC, Katritsis DG, et al. Comparison of effectiveness of ranolazine plus amiodarone versus amiodarone alone for conversion of recent-onset atrial fibrillation. Am J Cardiol. 2012;110(5):673\u20137.","journal-title":"Am J Cardiol."},{"key":"5_CR86","unstructured":"Menarini Group. Ranolazine in atrial fibrillation following an electricaL cardioversion (RAFFAELLO) [ClinicalTrials.gov identifier NCT01534962]. US National Institutes of Health, ClinicalTrials.gov (online). 2012. http:\/\/clinicaltrials.gov . Accessed 19 Nov 2012."},{"key":"5_CR87","unstructured":"Gilead Sciences. A study to evaluate the effect of ranolazine and dronedarone when given alone and in combination in patients with paroxysmal atrial fibrillation (HARMONY) [ClinicalTrials.gov identifier NCT01522651]. US National Institutes of Health, ClinicalTrials.gov (online). 2012. http:\/\/clinicaltrials.gov . Accessed 19 Nov 2012."},{"issue":"6","key":"5_CR88","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1016\/j.ahj.2012.03.018","volume":"163","author":"F Pelliccia","year":"2012","unstructured":"Pelliccia F, Pasceri V, Marazzi G, et al. A pilot randomized study of ranolazine for reduction of myocardial damage during elective percutaneous coronary intervention. Am Heart J. 2012;163(6):1019\u201323.","journal-title":"Am Heart J."}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-012-0005-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40265-012-0005-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-012-0005-z","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,28]],"date-time":"2023-06-28T15:34:49Z","timestamp":1687966489000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40265-012-0005-z"}},"subtitle":["A Review of Its Use as Add-On Therapy in Patients with Chronic Stable Angina Pectoris"],"short-title":[],"issued":{"date-parts":[[2013,1]]},"references-count":88,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2013,1]]}},"alternative-id":["5"],"URL":"https:\/\/doi.org\/10.1007\/s40265-012-0005-z","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,1]]}}}